5 stories
UK coverage on Peptide News Digest is dominated by MHRA enforcement on research peptides, NHS coverage of GLP-1s, and the broader UK peptide-clinic and aesthetic-medicine market.
Recent threads: MHRA warning letters and product seizures targeting peptide vendors selling BPC-157, TB-500, and other research peptides through online channels; NICE coverage decisions on Wegovy and Mounjaro for NHS prescribing; UK-based academic AMP work (Birmingham PEPITEM, Oxford); and the broader UK aesthetics market shift toward compounded peptide therapies.
Stories here cover MHRA enforcement, NHS coverage, and UK clinical work. See #mhra for direct MHRA actions and #uk-regulation for related rule-making.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
Under new UK guidance, GPs can prescribe semaglutide (Wegovy) to overweight patients who have had heart attacks, strokes, or serious circulation problems, expanding its use beyond weight management.
The Guardian editorial board criticizes RFK Jr.'s plan to open up ~14 injectable peptides, arguing the MAHA agenda replaces the precautionary principle with 'do your own research' rhetoric benefiting wellness profiteers.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.